Five Prime Therapeutics Inc. (FPRX) Shares Up 2.8%
Five Prime Therapeutics Inc. (NASDAQ:FPRX) shares shot up 2.8% during trading on Tuesday . The company traded as high as $46.89 and last traded at $46.41, with a volume of 205,241 shares changing hands. The stock had previously closed at $45.15.
A number of brokerages have commented on FPRX. Leerink Swann reaffirmed an “outperform” rating and issued a $58.00 price objective (up from $45.00) on shares of Five Prime Therapeutics in a report on Monday, August 8th. Jefferies Group set a $60.00 price objective on Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday, July 12th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $52.33.
The company has a market cap of $1.18 billion and a P/E ratio of 4.95. The stock has a 50 day moving average of $47.11 and a 200-day moving average of $42.38.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.07. The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. The business’s revenue was up 46.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.45) earnings per share. On average, equities research analysts anticipate that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current year.
In related news, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total transaction of $603,652.50. Following the sale, the director now directly owns 12,195 shares in the company, valued at $603,652.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction on Monday, August 1st. The stock was sold at an average price of $50.77, for a total value of $25,385.00. Following the sale, the director now owns 500 shares in the company, valued at $25,385. The disclosure for this sale can be found here.
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.